Topically applied pentoxifylline has no effect on allergic patch responses.

[1]  R. Hofmann-Wellenhof,et al.  Contact dermatitis, patch test response, and pentoxifyline What conclusions can be drawn at present? , 1996, Contact dermatitis.

[2]  R. Rietschel.  Reproducibility of patch-test results , 1996, The Lancet.

[3]  N. Balato,et al.  Effect of pentoxifylline on parch test response , 1996 .

[4]  R. Rietschel.  A pilot study of pentoxifylline for the prevention of poison ivy/oak reactions , 1995, Contact dermatitis.

[5]  J. Saurat,et al.  Nickel and skin irritants up-regulate tumor necrosis factor-alpha mRNA in keratinocytes by different but potentially synergistic mechanisms. , 1995, International immunology.

[6]  H. Maibach,et al.  Horizons in pharmacologic intervention in allergic contact dermatitis. , 1994, Journal of the American Academy of Dermatology.

[7]  P. Frosch,et al.  Reproducibility of patch tests. A multicenter study of synchronous left-versus right-sided patch tests by the German Contact Dermatitis Research Group. , 1994, Journal of the American Academy of Dermatology.

[8]  H. Ely.  Is pentoxifylline the drug of the decade? , 1994, Journal of the American Academy of Dermatology.

[9]  Y. Aragane,et al.  Pentoxifylline suppresses irritant and contact hypersensitivity reactions. , 1993, The Journal of investigative dermatology.

[10]  T. Luger,et al.  Pentoxifylline suppresses allergic patch test reactions in humans. , 1993, Archives of dermatology.

[11]  P. Vereerstraeten,et al.  EVIDENCE THAT PENTOXIFYLLINE REDUCES ANTI‐CD3 MONOCLONAL ANTIBODY‐INDUCED CYTOKINE RELEASE SYNDROME , 1991, Transplantation.

[12]  P. Vassalli,et al.  Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions , 1991, The Journal of experimental medicine.

[13]  Martine A. Collart,et al.  Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis , 1990, Nature.

[14]  P. Zabel,et al.  OXPENTIFYLLINE IN ENDOTOXAEMIA , 1989, The Lancet.

[15]  J. Ring,et al.  Reproducibility of patch tests. , 1989, Journal of the American Academy of Dermatology.

[16]  J. Ring,et al.  Reproducibility of patch test results: comparison of TRUE Test and Finn Chamber test results. , 1989, Journal of the American Academy of Dermatology.

[17]  P. Vassalli,et al.  Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis , 1989, The Journal of experimental medicine.

[18]  R. Strieter,et al.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline , 1988 .

[19]  W. J. Novick,et al.  Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline , 1988, Infection and immunity.

[20]  P. Vassalli,et al.  Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease , 1987, The Journal of experimental medicine.

[21]  L. F. Fajardo,et al.  Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. , 1987, Science.

[22]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[23]  J. Nater,et al.  On the persistence of positive patch test reactions to balsam of Peru, turpentine and nickel , 1973, The British journal of dermatology.

[24]  J. Morgan.  OBSERVATIONS ON THE PERSISTENCE OF SKIN SENSITIVITY WITH REFERENCE TO NICKEL ECZEMA. , 1953, The British journal of dermatology.